594 related articles for article (PubMed ID: 28611522)
1. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
[TBL] [Abstract][Full Text] [Related]
2. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
3. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP
J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
[TBL] [Abstract][Full Text] [Related]
5. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
6. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation.
Bargellini I; Vignali C; Cioni R; Petruzzi P; Cicorelli A; Campani D; De Simone P; Filipponi F; Bartolozzi C
Radiology; 2010 Apr; 255(1):289-300. PubMed ID: 20308465
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
10. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.
Bargellini I; Bozzi E; Campani D; Carrai P; De Simone P; Pollina L; Cioni R; Filipponi F; Bartolozzi C
Eur J Radiol; 2013 May; 82(5):e212-8. PubMed ID: 23332890
[TBL] [Abstract][Full Text] [Related]
11. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.
Zhang W; Xu AH; Wang W; Wu YH; Sun QL; Shu C
BMC Cancer; 2019 Nov; 19(1):1041. PubMed ID: 31690274
[TBL] [Abstract][Full Text] [Related]
12. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
13. Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study.
Pauwels X; Azahaf M; Lassailly G; Sergent G; Buob D; Truant S; Boleslawski E; Louvet A; Gnemmi V; Canva V; Mathurin P; Pruvot FR; Leteurtre E; Ernst O; Dharancy S
Cardiovasc Intervent Radiol; 2015 Jun; 38(3):685-92. PubMed ID: 25342136
[TBL] [Abstract][Full Text] [Related]
14. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
El-Gazzaz G; Sourianarayanane A; Menon KV; Sanabria J; Hashimoto K; Quintini C; Kelly D; Eghtesad B; Miller C; Fung J; Aucejo F
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):34-41. PubMed ID: 23392796
[TBL] [Abstract][Full Text] [Related]
15. Response to transarterial chemoembolization as a selection criterion for resection of hepatocellular carcinomas.
Lei JY; Zhong JJ; Yan LN; Zhu JQ; Wang WT; Zeng Y; Li B; Wen TF; Yang JY;
Br J Surg; 2016 Jun; 103(7):881-90. PubMed ID: 27027978
[TBL] [Abstract][Full Text] [Related]
16. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
17. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation.
Terzi E; Ray Kim W; Sanchez W; Charlton MR; Schmeltzer P; Gores GJ; Andrews JC; Smyrk TC; Heimbach JK
Liver Transpl; 2015 Feb; 21(2):248-57. PubMed ID: 25371111
[TBL] [Abstract][Full Text] [Related]
18. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.
Sandow T; Pavlus J; Field D; Lacayo E; Cohen E; Lynskey G; Caridi T; Buckley D; Cardella J; Kallakury B; Spies J; Kim AY
J Vasc Interv Radiol; 2019 Jul; 30(7):995-1003. PubMed ID: 31109853
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
20. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
